Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ISRNASDAQ:PROFNASDAQ:SGHTNASDAQ:TLSI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeISRIsoray$0.37$0.19▼$0.45$54.57M1.48290,697 shs145,000 shsPROFProfound Medical$6.35-5.8%$5.27$3.90▼$11.42$190.84M0.4864,966 shs13,196 shsSGHTSight Sciences$4.06-4.9%$3.42$2.03▼$8.45$209.89M2.46217,084 shs225,323 shsTLSITriSalus Life Sciences$5.59+3.9%$5.39$3.50▼$6.04$211.52M0.4743,670 shs364,441 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceISRIsoray0.00%0.00%0.00%0.00%0.00%PROFProfound Medical0.00%-2.91%+23.78%-6.75%-29.37%SGHTSight Sciences0.00%-1.69%+23.78%+40.48%-36.56%TLSITriSalus Life Sciences0.00%+7.71%+4.49%-0.89%-2.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationISRIsorayN/AN/AN/AN/AN/AN/AN/AN/APROFProfound Medical2.0871 of 5 stars3.52.00.00.00.62.50.6SGHTSight Sciences1.3932 of 5 stars1.14.00.00.02.33.30.6TLSITriSalus Life Sciences3.037 of 5 stars3.65.00.00.00.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceISRIsoray 0.00N/AN/AN/APROFProfound Medical 3.00Buy$11.5081.10% UpsideSGHTSight Sciences 2.29Hold$4.02-1.07% DownsideTLSITriSalus Life Sciences 3.25Buy$10.7592.31% UpsideCurrent Analyst Ratings BreakdownLatest ISR, SGHT, PROF, and TLSI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025SGHTSight SciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/22/2025SGHTSight SciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.20 ➝ $3.605/9/2025PROFProfound MedicalRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Moderate Buy5/9/2025SGHTSight SciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$2.50 ➝ $3.004/23/2025PROFProfound MedicalLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $11.004/9/2025SGHTSight SciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold3/28/2025TLSITriSalus Life SciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookISRIsoray$10.80M0.00N/AN/A$0.43 per share0.00PROFProfound Medical$10.68M17.87N/AN/A$2.01 per share3.16SGHTSight Sciences$79.87M2.63N/AN/A$1.72 per share2.36TLSITriSalus Life Sciences$29.43M7.19N/AN/A($0.83) per share-6.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateISRIsoray-$7.27M-$0.07N/AN/AN/A-115.91%-17.12%-16.15%N/APROFProfound Medical-$27.82M-$1.22N/AN/AN/A-269.35%-70.41%-57.22%8/6/2025 (Estimated)SGHTSight Sciences-$51.51M-$0.98N/AN/AN/A-63.24%-54.62%-34.92%7/30/2025 (Estimated)TLSITriSalus Life Sciences-$30.05M-$1.12N/AN/AN/A-84.67%N/A-111.63%8/13/2025 (Estimated)Latest ISR, SGHT, PROF, and TLSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025TLSITriSalus Life Sciences-$0.20-$0.33-$0.13-$0.39$9.04 million$9.17 million5/8/2025Q1 2025PROFProfound Medical-$0.29-$0.36-$0.07-$0.36$4.78 million$2.62 million5/8/2025Q1 2025SGHTSight Sciences-$0.29-$0.28+$0.01-$0.28$16.51 million$17.51 million3/27/2025Q4 2024TLSITriSalus Life Sciences-$0.35-$0.35N/A-$0.40$8.12 million$8.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthISRIsorayN/AN/AN/AN/AN/APROFProfound MedicalN/AN/AN/AN/AN/ASGHTSight SciencesN/AN/AN/AN/AN/ATLSITriSalus Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioISRIsorayN/A14.3813.99PROFProfound Medical0.0911.3110.03SGHTSight Sciences0.5110.479.99TLSITriSalus Life SciencesN/A2.141.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipISRIsoray11.32%PROFProfound Medical47.86%SGHTSight Sciences55.51%TLSITriSalus Life Sciences2.58%Insider OwnershipCompanyInsider OwnershipISRIsoray2.42%PROFProfound Medical1.52%SGHTSight Sciences30.90%TLSITriSalus Life Sciences27.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableISRIsorayN/A142.11 million138.67 millionNot OptionablePROFProfound Medical15030.05 million29.60 millionOptionableSGHTSight Sciences21051.70 million35.72 millionOptionableTLSITriSalus Life Sciences10637.84 million27.43 millionNot OptionableISR, SGHT, PROF, and TLSI HeadlinesRecent News About These CompaniesTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Down 70.0% in MayJune 13, 2025 | marketbeat.comResearch Analysts Set Expectations for TLSI FY2026 EarningsJune 12, 2025 | americanbankingnews.comCantor Fitzgerald Forecasts TLSI FY2026 EarningsJune 10, 2025 | marketbeat.comBank of America Corp DE Raises Holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSI)June 8, 2025 | marketbeat.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Consensus Recommendation of "Buy" by BrokeragesJune 8, 2025 | marketbeat.comTriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. PatienceMay 30, 2025 | businesswire.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Sees Significant Growth in Short InterestMay 30, 2025 | marketbeat.comRoth Capital Issues Pessimistic Forecast for TLSI EarningsMay 25, 2025 | marketbeat.comCantor Fitzgerald Issues Negative Estimate for TLSI EarningsMay 23, 2025 | marketbeat.comJodi Devlin Sells 4,764 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) StockMay 22, 2025 | insidertrades.comTriSalus outlines at least 50% revenue growth for 2025 as new Medicare code expands addressable marketMay 15, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Conference Call TranscriptMay 15, 2025 | seekingalpha.comTriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comTriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 GuidanceMay 15, 2025 | businesswire.comTriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference CallMay 12, 2025 | businesswire.comTriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial ResultsApril 30, 2025 | finance.yahoo.comTriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?April 9, 2025 | zacks.comTriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?April 9, 2025 | zacks.comTriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still RisksMarch 30, 2025 | seekingalpha.comTrisalus outlines 50% revenue growth target for 2025 driven by TriNav expansion and new market penetrationMarch 27, 2025 | msn.comTriSalus Life Sciences’ Q4 Loss Exceeds Projections, Revenue Tops Estimates – Retail Stays PessimisticMarch 27, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden Dome3 Beaten-Down Stocks Trading 50% Below Their 52-Week HighsBy Leo Miller | May 27, 2025View 3 Beaten-Down Stocks Trading 50% Below Their 52-Week HighsChime’s Smart IPO: Half the Valuation, Double the StrengthBy Jeffrey Neal Johnson | June 18, 2025View Chime’s Smart IPO: Half the Valuation, Double the StrengthIs D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker?By Nathan Reiff | June 16, 2025View Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker?NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s WhyBy Thomas Hughes | May 29, 2025View NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s WhyISR, SGHT, PROF, and TLSI Company DescriptionsIsoray NYSE:ISRIsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.Profound Medical NASDAQ:PROF$6.35 -0.39 (-5.79%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$6.38 +0.04 (+0.55%) As of 06/20/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.Sight Sciences NASDAQ:SGHT$4.06 -0.21 (-4.92%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$4.06 0.00 (0.00%) As of 06/20/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.TriSalus Life Sciences NASDAQ:TLSI$5.59 +0.21 (+3.90%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$5.60 +0.02 (+0.27%) As of 06/20/2025 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
